Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
X4 Pharmaceuticals Inc
Arsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies for the targeted immunotherapy of serious infections.
IPO Date: May 13, 2022
Sector: Healthcare
Industry: Biotech
Market Cap: $5.5M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.07 | 5.20%
Avg Daily Range (30 D): $0.04 | 5.54%
Avg Daily Range (90 D): $0.05 | 4.54%
Institutional Daily Volume
Avg Daily Volume: .56M
Avg Daily Volume (30 D): .22M
Avg Daily Volume (90 D): .48M
Trade Size
Avg Trade Size (Sh.): 230
Avg Trade Size (Sh.) (30 D): 356
Avg Trade Size (Sh.) (90 D): 301
Institutional Trades
Total Inst.Trades: 10
Avg Inst. Trade: $.93M
Avg Inst. Trade (30 D): $2.54M
Avg Inst. Trade (90 D): $2.54M
Avg Inst. Trade Volume: .18M
Avg Inst. Trades (Per Day): 5
Market Closing Trades
Avg Closing Trade: $.53M
Avg Closing Trade (30 D): $M
Avg Closing Trade (90 D): $M
Avg Closing Volume: 142.9K
       
News
Aug 14, 2024 @ 9:45 PM
Actelis Networks Reports Q2 2024 Results: 372% Seq...
Source: N/A
Jul 11, 2024 @ 9:16 AM
Why WD-40 Shares Are Trading Higher By Over 12%; H...
Source: Avi Kapoor
Jul 10, 2024 @ 8:06 PM
Actelis Receives $260,000 Order for Major Mid-Atla...
Source: Actelis Networks, Inc.
Jun 28, 2024 @ 12:30 PM
Actelis Receives Order from Major German Municipal...
Source: Actelis Networks, Inc.
Jun 27, 2024 @ 8:25 PM
Actelis Continues to Expand International Footprin...
Source: Actelis Networks, Inc.
Financials
  TTM Q4 2024 FY 2024
Basic EPS $-.85 $-.26 $-.85
Diluted EPS $-.85 $-.26 $-.85
Revenue $ 7.76M $ 1.06M $ 7.76M
Gross Profit $ 4.27M $ .36M $ 4.27M
Net Income / Loss $ -4.37M $ -1.8M $ -4.37M
Operating Income / Loss $ -3.76M $ -1.64M $ -3.76M
Cost of Revenue $ 3.49M $ .7M $ 3.49M
Net Cash Flow $ -3.25M $ -.27M $ -3.25M
PE Ratio    
Splits
Apr 19, 2023:   10:1
Mar 14, 2019:   6:1